BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase I
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Galectin Therapeutics To Host Webcast To Discuss Findings From Cohort 2 Of Phase 1 Clinical Trial Of GR-MD-02 In Fatty Liver Disease With Advanced Fibrosis 7/25/2014
Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 1 Study Of MVA-BN® Brachyury In Advanced Cancer 7/24/2014
Advanced Biologics Publishes Additional Osteoamp® Abstracts In The Bone And Joint Journal 7/24/2014
Media Advisory: AFFiRiS AG Presents Early Clinical Data On A First-Of-Its-Kind Parkinson's Disease Vaccine 7/24/2014
Amunix, Inc. And PolyPeptide Publish Multivalent Antiviral XTEN-Peptide Conjugates In Vivo Studies In American Chemical Society's Journal 7/24/2014
Biosceptre Announces Positive Phase I Results For BIL-010t To Treat Basal Cell Carcinoma 7/23/2014
Dyax Corp. (DYAX) Announces Publication Of Scientific Data For DX-2930 In Peer-Reviewed Journals 7/23/2014
Ligand Pharmaceuticals Inc. (LGND) Partner SAGE Therapeutics Receives Fast Track Designation For Captisol-enabled SAGE-547 To Treat Status Epilepticus 7/23/2014
Dompe Announces The FDA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Neurotrophic Keratitis 7/23/2014
SAGE Therapeutics Receives Fast Track Designation For Lead Compound SAGE-547 To Treat Status Epilepticus 7/22/2014
MYOS (MYOS) Reports Positive Top-Line Clinical Study Results of Fortetropin's Muscle Building Activity in Male Subjects 7/22/2014
Jazz Pharmaceuticals plc (JAZZ) And Concert Pharmaceuticals, Inc. (CNCE) Provide A Phase 1 Clinical Trial Update On JZP-386 7/22/2014
Galectin Therapeutics Announces First Patient Dosed In Cohort 1 Of Phase 1B Clinical Trial Of GR-MD-02 In Combination With Ipilimumab In Metastatic Melanoma 7/22/2014
Genocea Biosciences HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses In Vaccinated Subjects 7/22/2014
ERYtech Pharma Announces Enrollment Of First Patient In Phase I/II Study Of ERY-ASP In Acute Lymphoblastic Leukemia In The United States 7/22/2014
ZIOPHARM, Inc. Announces Expansion Of Ground-Breaking Synthetic Immuno-Oncology Programs With Intrexon And Clinical Program Update 7/22/2014
Regulus Therapeutics, Inc. Receives Orphan Drug Designation For RG-012, A microRNA Therapeutic For The Treatment Of Alport Syndrome 7/21/2014
Ignyta (RXDX) Announces Initiation Of STARTRK-1 Global Phase I/II Clinical Trial Of RXDX-101 7/21/2014
Synthetic Biologics, Inc. (SYN)' Academic Collaborator To Present Novel Monoclonal Antibody Combination For Treating Whooping Cough (Pertussis) At Gordon Research Conference 7/21/2014
Tekmira Pharmaceuticals Corporation (TKMR) Provides Update on TKM-Ebola Phase I Clinical Hold 7/21/2014
Tekmira Pharmaceuticals Corporation (TKMR) Provides Update On TKM-Ebola Phase I Clinical Hold 7/21/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
Rexahn Pharmaceuticals, Inc. (RNN) Provides Update On Phase I Supinoxin Trial In Cancer Patients With Solid Tumors 7/18/2014
FDA Lifts Partial Clinical Hold For Concert Pharmaceuticals, Inc. (CNCE)'s CTP-354 7/17/2014
Nuvilex (NVLX) And Austrianova Announce Results Of Clinical Trial In Dogs With Mammary Tumors Treated With Cell-In-A-Box® Plus Cyclophosphamide 7/17/2014
Silk Road Medical Completes Enrollment In The ROADSTER Clinical Trial For Carotid Artery Disease 7/17/2014
Alkermes plc (ALKS) Announces Initiation Of Phase 1 Clinical Study Of ALKS 8700 For Treatment Of Multiple Sclerosis 7/17/2014
Dipexium Pharmaceuticals (DPRX) Announces Successful Completion Of Phase 1 Skin Irritation Trial Of Locilex® 7/17/2014
Juvenile Diabetes Research Foundation Partner ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Announces Key Project Milestone To Advance Innovative Encapsulated Cell Replacement Therapy Product For Type 1 Diabetes 7/17/2014
Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60 7/17/2014
Capricor Therapeutics, Inc. Announces Encouraging Results From Phase1 ALLSTAR Trial; Phase 2 Trial Underway 7/16/2014
Northwest Biotherapeutics (NWBO) Announces Completion Of DCVax®-Direct Phase I Trial Recruitment 7/16/2014
BioLineRx Ltd. Announces Results From Phase 1/2 Study For Celiac Treatment 7/16/2014
ChromaDex, Inc. Initiates First Human Clinical Study To Confirm ChromaDex's NIAGEN™ Nicotinamide Riboside Will Increase NAD+ 7/16/2014
ImQuest Pharmaceuticals, Inc. Receives FDA Approval To Initiate Clinical Trials Of A Vaginal Gel For The Prevention Of HIV Transmission To Women 7/16/2014
Egalet Reports Positive Top-Line Results From Category 1 Abuse Deterrence Studies Demonstrating Egalet-001 Resists Physical And Chemical Manipulation 7/15/2014
Cellceutix (CTIX) Announces Breakthrough In The Formulation Of Its Novel Antibiotic Brilacidin™, Plans Studies To Treat Diabetic Foot Ulcers 7/15/2014
Helix Biopharma (CC:HBP) Initiates Enrollment For Ninth Cohort In Polish Phase I/II Clinical Study Of Its Lung Cancer Drug Candidate L-DOS47 7/15/2014
Novartis AG (NVS) To Test Alzheimer's Drugs In Patients Without Symptoms 7/15/2014
QLT Inc. (QLTI) Announces Publication In The Lancet Of Phase 1b Data For QLT091001 In Leber Congenital Amaurosis Due To LRAT Or RPE65 Mutations 7/14/2014
Trevi Therapeutics Announces Initiation Of A Pivotal Study Of Nalbuphine ER In Uremic Pruritus 7/14/2014
Probiodrug AG Presents Development Overview Of PQ912, Probiodrug’s QC-Inhibitor For Alzheimer’s Disease 7/10/2014
Dezima Pharma Extends Clinical Development Program For Its CETP Inhibitor TA-8995 7/9/2014
Soligenix (SNGX) Announces Combination Vaccine For Ricin And Anthrax Achieves Simultaneous Protection 7/9/2014
Threshold Pharmaceuticals, Inc. (THLD) Announces Initiation Of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") In Final Stage Of Ongoing Phase 1/2 Trial Of Patients With Relapsed/Refractory Multiple Myeloma 7/9/2014
Novartis AG (NVS) Wins Breakthrough Status For New Leukemia Treatment CTL019 7/8/2014
Cesca Therapeutics Management Provides Regulatory Update On Its Proposed U.S. Pivotal Critical Limb Ischemia Clinical Trial 7/8/2014
Cortice Biosciences Announces Enrollment Of A Phase 1 Clinical Trial Evaluating TPI 287 In Rare Tauopathy Diseases 7/7/2014
GenSpera To Present Ongoing HCC Trial Data At APPLE 2014 Congress July 12th In Taipei 7/7/2014
Reaction Biology Corp. Receives National Institutes of Health (NIH) Grant Award For Epigenetic Database 7/7/2014
BeiGene Co.,Ltd Enrolls First Patient In Phase 1 Study Of BGB-290 7/7/2014
Glenmark Pharmaceuticals's Novel Monoclonal Antibody GBR 830 For Treatment Of Autoimmune Diseases Entering Human Trials 7/3/2014
Akashi Therapeutics Presents Positive Clinical Data On HT-100 In Patients With Duchenne Muscular Dystrophy 7/3/2014
Akashi Therapeutics Receives Fast Track Designation For HT-100 From FDA For The Treatment Of Duchenne Muscular Dystrophy 7/3/2014
Tekmira Pharmaceuticals Corporation (TKMR) Sinks As The FDA Puts Ebola Study On Hold; Stock Down -15.54% At Market Close (July 3, 2014) 7/3/2014
Galapagos NV (GLPG.BR) Initiates Phase 1 Study With GLPG1690, Triggering €6.6 M Milestone In The Alliance With Janssen Pharmaceutica N.V. 7/1/2014
GlycoVaxyn AG Announces The Initiation Of A Phase I Clinical Trial In Collaboration With Janssen Pharmaceutical Inc. For A Vaccine Against Extra-Intestinal Pathogenic Escherichia Coli Causing Urinary Tract Infection 7/1/2014
Genocea Biosciences Announces Positive Top-Line 12-Month Follow-Up Data From Phase 1/2a Clinical Trial For HSV-2 Immunotherapy GEN-003 7/1/2014
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces Additional Data Demonstrating Efficacy Of AEOL 10150 As A Medical Countermeasure Against Exposure To Nerve Agents, Sulfur Mustard Gas And Nitrogen Mustard Gas 7/1/2014
CritiTech Announces Positive Results From Phase I Trial Of Nanotax® For Intraperitoneal Cancers 7/1/2014
Northwestern Medicine Release: Researchers Seek to Tackle Transplant Tolerance Using Patients' Own T Cells 6/30/2014
Nora Therapeutics Presents Phase 1 Data On NT100 At The European Society Of Human Reproduction And Embryology Annual Meeting 6/30/2014
Xenetic Biosciences Announces Ongoing Safety Data From Phase 2 Trial Of Erepoxen® 6/30/2014
Anavex Life Sciences Corp. (AVXL.OB) Announces Report Expanding Opportunity For Therapeutic Application Of Anavex Compounds 6/30/2014
Ampio Pharmaceuticals, Inc. (AMPE) Initiates Study of Multiple Injections Of Ampion™ Into The Knees Of Patients With OA Of The Knee To Assess Its Healing And Cartilage Regeneration Effects 6/30/2014
First Patient Enrolled In FDA Phase 1/2a Clinical Trial With Biolight's Controlled-Release Latanoprost Insert For The Treatment Of Glaucoma 6/30/2014
Retrophin, Inc. (RTRX) Slumps As Patient On Key Drug Shows High Liver Enzyme Levels 6/27/2014
Antibe Therapeutics Inc. Announces First Human Dose Of ATB-346 In Phase I Clinical Trial 6/27/2014
Boehringer Ingelheim Corporation's Investigational Antidote For Pradaxa® Grabs FDA Breakthrough Therapy Designation 6/26/2014
Targacept, Inc. (TRGT) Initiates Exploratory Study Of TC-6499 In Diabetic Gastroparesis 6/25/2014
Calimmune Approved To Treat Second Group In HIV Stem Cell Gene Modification Study 6/25/2014
Debiopharm And TCG Lifesciences Announce Successful Completion Of First Phase Of Research Collaboration On Discovery Of Novel Antibiotics 6/24/2014
Results Of Phase 1b Clinical Trial Comparing Trevena, Inc. (TRVN)’s TRV130 To Morphine Published In The Journal Pain 6/24/2014
Ultragenyx Pharmaceuticals Announces Results From Phase 1/2 Study Of KRN23 In X-Linked Hypophosphatemia In Adults 6/24/2014
Regado Biosciences, Inc. (RGDO)' REG2 Demonstrates Dose And Concentration-Dependent Suppression Of Thrombin Generation 6/23/2014
Ligand Pharmaceuticals Inc. (LGND) Announces Presentation Of Positive Data From A Phase 1 Study On The Effect Of The SERM Lasofoxifene To Increase Testosterone Levels In Men 6/23/2014
Trevena, Inc. (TRVN) Announces Positive Phase 1 Results For TRV734 For Acute And Chronic Pain 6/23/2014
Clovis Oncology (CLVS) Announces First Patient Enrolled In TIGER2 Study 6/23/2014
Triphase Accelerator Announces Orphan Drug Designation In The European Union For Marizomib For Multiple Myeloma 6/23/2014
Enteris Biopharma Oral Peptide Delivery Technology Enables Key Clinical Milestone For Acute And Chronic Pain Drug 6/20/2014
Northwest Biotherapeutics (NWBO) Biotechnology Industry Organization (BIO) Reaffirms DCVAX®-Direct Clinical Trial Interim Data Announcements 6/20/2014
StemCells Inc. (STEM) Announces Closure Of Enrollment In Phase 1/2 Dry Age-Related Macular Degeneration Trial 6/20/2014
NeoStem, Inc. Announces University of California, San Francisco (UCSF) Presentation Of Phase 1 Results For T Regulatory Cell Immunotherapy For Type 1 Diabetes At American Diabetes Association Annual Meeting 6/19/2014
Aratana Therapeutics (PETX) Initiates And Doses First Patient In Market Development Studies Of AT-005 For Treating Canine T-Cell Lymphoma 6/19/2014
NeuralStem Inc. NSI-189 Select Data To Be Presented At Neuropsychopharmacology Congress 6/19/2014
StemCells Inc. (STEM) Interim Results Show Improvement In Visual Function And Slowing Of Disease Progression In Phase 1/2 Dry AMD Trial 6/19/2014
MacroGenics, Inc. (MGNX) Initiates Phase 1 Study Of MGD006 For The Treatment Of Acute Myeloid Leukemia 6/19/2014
GlycoMimetics, Inc. (GLYC) Initiates First Clinical Trial Of GMI-1271 As Potential Treatment For Blood-Related Cancers 6/19/2014
Enrollment Continues Into Bio-Path Holdings, Inc. (BPTH) Phase I Clinical Trial 6/19/2014
Antibe Therapeutics Inc. Receives Approval From Health Canada To Begin Human Clinical Testing 6/19/2014
OncoMed Pharmaceuticals, Inc. (OMED) Provides Update on FZD8-Fc (OMP-54F28) Phase I Clinical Trials 6/19/2014
Cara Therapeutics, Inc. (CARA) Initiates Phase 1a/1b Trial Of Tablet Formulation Of Oral CR845 For The Treatment Of Acute And Chronic Pain 6/18/2014
Gradalis Inc. Announces Presentation Of New Data 6/18/2014
Asmacure Announces Top-Line Clinical Results For ASM-024 DPI In Ph 1/2a Trial 6/18/2014
NeuralStem Inc. Final Phase I Depression Data Presented At The American Society Of Clinical Psychopharmacology Annual Meeting 6/18/2014
FutureCeuticals Release: Human Clinical Study Further Indicates FruiteX-B® Calcium Fructoborate Provides Fast-Acting Joint And Flex Benefits 6/17/2014
FDA Release: DNAtrix, Inc. Grants Fast Track Status To DNAtrix Drug DNX-2401 For Recurrent Glioblastoma 6/17/2014
Cambridge-Based bluebird bio (BLUE)'s Gene Therapy Quickly Halts Blood Disease In Small Study; Stock Up 32.08% At Market Close (June 16, 2014) 6/17/2014
Redwood City's OncoMed Pharmaceuticals, Inc. (OMED) Voluntarily Halts Early-Stage Trials for Two Cancer Drugs 6/16/2014
Advaxis, Inc. Evaluates Higher Dose And Repeat Cycles Of ADXS-HPV In Phase 1/2 Cervical Cancer Trial 6/16/2014
Ligand Pharmaceuticals Inc. (LGND) Announces Successful First-In-Human Trial Results For Glucagon Program 6/16/2014
Agios Pharmaceuticals (AGIO) Announces Orphan Drug Designation Of AG-221 For Treatment Of Acute Myelogenous Leukemia 6/16/2014
Cellceutix (CTIX) Clinical Trial Of Anti-Cancer Drug Kevetrin Entering Eighth Cohort 6/16/2014
Boston Biomedical Announces Clinical Data Presentation Of Its Cancer Stem Cell Inhibitor Programs 6/16/2014
Islet Sciences Presents Positive Clinical Results For Best-In-Class SGLT2 Inhibitor At American Diabetes Association Annual Meeting 6/16/2014
BioLineRx Ltd. Receives Approval To Commence Phase 1 Trial For Novel Stem Cell Mobilization Treatment 6/16/2014
New Agios Pharmaceuticals (AGIO) Clinical Data From Ongoing Phase 1 Trial Of AG-221 Continue To Show Complete And Durable Remissions In Patients With Difficult To Treat Hematologic Malignancies 6/16/2014
Fibrocell Science, Inc. Receives Orphan Drug Designation For Genetically-Modified Autologous Human Fibroblasts To Advance Treatment Development for Recessive Dystrophic Epidermolysis Bullosa (RDEB) 6/13/2014
Protalex, Inc. (PRTX) Announces Data from U.S. Phase 1(b) Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients Presented At The 2014 EULAR Annual European Congress of Rheumatology 6/13/2014
Karyopharm Therapeutics (KPTI) Announces First Combination Data Of Selinexor With Low-Dose Dexamethasone In Heavily Pretreated Multiple Myeloma Patients 6/13/2014
Acetylon Pharmaceuticals Reports Ricolinostat (ACY-1215) Is Active And Well-Tolerated In Ongoing Phase 1b Studies In Patients With Refractory Multiple Myeloma At The 19th Congress Of The European Hematology Association 6/13/2014
Geron Corporation (GERN) Jumps As FDA Lifts Partial Hold On Myelofibrosis IST 6/12/2014
Diagram Release: First Patient Enrolled In Investigator Initiated REDUCE Study 6/12/2014
Ruthigen Cleared To Initiate Human Clinical Trials For RUT58-60 In The U.S. 6/12/2014
Capstone Therapeutics (CAPS) Announces Initiation Of Dosing For AEM-28 Phase 1b/2a Human Clinical Trial In Refractory Hypercholesterolemic Subjects 6/12/2014
Basilea Pharmaceutica (BSLN.SW) Initiates Phase 1 Combination Study With Its Gram-Negative Antibiotic BAL30072 And Meropenem 6/12/2014
Interim Results Of First Clinical Trial Of Themis Bioscience’s Vaccine Candidate Against Chikungunya Fever Prove Successful 6/12/2014
Marina Biotech, Inc. (MRNA) Announces That Licensee Mirna Therapeutics, Inc. Enrolls First Patient In Hematologic Malignancy Cohort Of On-Going Trial 6/12/2014
Oncobiologics Inc. Launches Phase I Clinical Trial For ONS-3010 Biosimilar Version Of Humira® 6/12/2014
Northwest Biotherapeutics (NWBO) Release: DCVAX-Direct Trial Update Indicates Further Positive Responses; 3 Case Studies Show No Live Tumor Cells In Injected Tumors 6/11/2014
Capstone Therapeutics Announces Initiation Of Dosing For AEM-28 Phase 1b/2a Human Clinical Trial In Refractory Hypercholesterolemic Subjects 6/11/2014
Achillion Pharmaceuticals, Inc. (ACHN) Surges As The FDA Lifts Hold On Hepatitis C Trial; Stock Up +83.29% At Market Close (June 10, 2014) 6/11/2014
Inovio Pharmaceuticals (INO) Initiates Immune Therapy Trial For Head & Neck Cancer Caused By HPV 6/10/2014
Mirna Therapeutics, Inc.Announces First Patient Enrolled In Hematological Malignancy Cohort Of Its Phase 1 Clinical Trial 6/10/2014
Agios Pharmaceuticals (AGIO) Initiates Multiple Ascending Dose Trial In Healthy Volunteers Of AG-348 For The Potential Treatment Of PK Deficiency, A Rare, Hemolytic Anemia 6/9/2014
Immunomedics, Inc. (IMMU) Announces Orphan Drug Designation For IMMU-132 For Pancreatic Cancer Therapy 6/9/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1 Study Of ISIS-DMPK Rx To Treat Myotonic Dystrophy Type 1 6/9/2014
D-Pharm Ltd.'s Anti-Epileptic Drug DP-VPA Is Granted Fast Track Status By The Chinese Food And Drug Administration (CFDA) 6/9/2014
Genentech (RHHBY) Bladder Cancer Med Anti-PDL1 (MPDL3280A) Nabs Breakthrough Status 6/9/2014
Medgenics, Inc. Announces First Patient Implanted In Phase 1/2 Clinical Trial Of MDGN-201 (EPODURE) 6/6/2014
ImaginAb, Inc. Presents Initial Phase I/Iia Results For Prostate Imaging Agent At Society of Nuclear Medicine And Molecular Imaging (SNMMI) Annual Meeting 6/6/2014
Advaxis, Inc.'s ADXS-Cher2 Immunotherapy Continues To Demonstrate Significantly Prolonged Survival In Canine Osteosarcoma 6/6/2014
Immune Design Corporation Announces Treatment Of First Patient In Phase 1 Clinical Trial Of LV305 Immuno-Oncology Agent 6/5/2014
Momenta Pharmaceuticals, Inc. (MNTA) Receives Orphan Drug Designation For Necuparanib (Formerly M402) In Pancreatic Cancer 6/5/2014
Curis, Inc. (CRIS) Announces Re-Initiation Of Patient Dosing In CUDC-427 Monotherapy Clinical Trial 6/5/2014
Edge Therapeutics Initiates Enrollment Of Second Cohort In Phase 1/2 NEWTON Study Of EG-1962 For Improvement Of Outcome After Ruptured Brain Aneurysm 6/5/2014
SAGE Therapeutics Presents Preliminary SAGE-547 Clinical Data At Epilepsy Pipeline Conference 6/5/2014
Ocugen, Inc. Receives Orphan Designation For OCU100 To Treat Retinitis Pigmentosa 6/5/2014
AstraZeneca PLC (AZN) Shows Off Its Cancer Pipeline 6/4/2014
Kadmon Corporation Announces The Initiation Of A Phase 1b/2a Study Of KD019 And Trastuzumab In HER2-Positive Metastatic Breast Cancer 6/4/2014
Advanced Cancer Therapeutics Enters Phase 1 Human Clinical Trials With First-in-Class Anti-Cancer Drug Candidate 6/4/2014
United Cannabis Corporation Release: FDA Approval Of Medical MJ: Phase I Human Studies Explored By Team Of Experts 6/4/2014
Merrimack Pharmaceuticals Inc. (MACK) Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs At The 2014 American Society of Clinical Oncology Annual Meeting 6/3/2014
Cerulean Pharma Inc. (CERU) Announces CRLX101 Combination Data At 2014 American Society of Clinical Oncology Annual Meeting 6/3/2014
Arena Pharmaceuticals, Inc. (ARNA) Initiates Phase 1b Clinical Trial Of APD334 For Autoimmune Diseases 6/3/2014
Protalex, Inc. (PRTX) Announces Preliminary Unblinded Findings From Cohorts 1-4 Of U.S. Phase 1b Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 6/3/2014
AstraZeneca PLC (AZN)’s MedImmune (AZN) Presents Encouraging Immunotherapy Data at American Society of Clinical Oncology 2014 6/3/2014
Xcovery Presents Interim Phase 1 Results Of X-396 In ALK Positive NSCLC At The American Society of Clinical Oncology Annual Meeting 6/3/2014
AbbVie (ABBV) Touts Early Phase 1 Success With Brain Cancer Drug 6/2/2014
AbbVie (ABBV) Presents New Results From Studies Of Investigational Oncology Compound ABT-199/GDC-0199 At The 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014
Ariad Pharmaceuticals, Inc. (ARIA) Announces Longer-Term Safety And Efficacy Data Of Ponatinib From PACE And Phase 1 Clinical Trials 6/2/2014
Data on Merck & Co., Inc. (MRK)’s Pembrolizumab From Largest Study To Date Of Investigational Anti-PD-1 Antibody In Advanced Melanoma Highlighted At American Society of Clinical Oncology 2014 6/2/2014
Karyopharm Therapeutics (KPTI) Updates Data For Selinexor In Solid Tumors At 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014
Seattle Genetics, Inc. (SGEN) Presents Data from Phase 1 Clinical Trial Of Antibody-Drug Conjugate (ADC) SGN-CD19A In Non-Hodgkin Lymphoma At American Society of Clinical Oncology Annual Meeting 6/2/2014
Immunomedics, Inc. (IMMU) Reports IMMU-130 Is Active In Patients With Irinotecan-Refractory Colorectal Cancer 6/2/2014
Ignyta Announces Interim Data From RXDX-101 Phase I Clinical Trial 6/2/2014
AVEO Oncology (AVEO) Announces Presentation Of AV-203 Phase 1 Results At 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014
Galena Biopharma  (GALE) Presents GALE-301 Phase 1 Data At The American Society of Clinical Oncology 50th Annual Meeting 6/2/2014
Karyopharm Therapeutics (KPTI) Provides Data Update For Selinexor In Non-Hodgkin's Lymphoma And Acute Myeloid Leukemia At 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014
Clovis Oncology (CLVS) Announces Encouraging Data From Phase 1/2a Study Evaluating Lucitanib In Advanced Solid Tumors 6/2/2014
Clovis Oncology (CLVS)’s CO-1686 Demonstrates Compelling Clinical Activity And Progression-Free Survival (PFS) In Updated Phase 1/2 Study Results In Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) 6/2/2014
Clovis Oncology (CLVS)’s Phase 1 Study Of Rucaparib Demonstrates Compelling Clinical Activity and Safety In Patients With Solid Tumors 6/2/2014
Immunomedics, Inc. (IMMU) Reports Final Efficacy Results Of Phase Ib Trial With Yttrium-90-Labeled Clivatuzumab Tetraxetan In Patients With Metastatic Pancreatic Cancer 6/2/2014
Basilea Pharmaceutica (BSLN.SW)'s Oncology Drug Candidate BAL101553 Shows First Evidence Of Antitumor Activity In Phase 1 Study 6/2/2014
Nanobiotix Presents Successful Phase I Results For Its Lead Nanomedicine Product NBTXR3 At American Society of Clinical Oncology 6/2/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Presentation Of Positive Updated Results From Ongoing MD Anderson Cancer Center-Sponsored Trial Of Vosaroxin In AML And High-Risk MDS At American Society of Clinical Oncology 2014 Annual Meeting 6/2/2014
Verastem, Inc. (VSTM) Presents Updated Clinical Data From VS-6063 And Paclitaxel Combination Phase 1/1b Study In Patients With Ovarian Cancer At The 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014
Scancell: Update On Phase 1/2 Clinical Trial Of SCIB1 In Stage III/IV Melanoma 6/2/2014
Aduro Biotech Announces American Society of Clinical Oncology Presentation Of Promising Results From Phase 1b Clinical Trial Of Its Novel Immunotherapy For The Treatment Of Mesothelioma 6/2/2014
HealthCare Pharmaceuticals Announces American Society of Clinical Oncology Presentation Of DKN-01 Clinical Study In Non-Small Cell Lung Cancer And First Patients Dosed In Clinical Study For DKK1+ Esophageal Cancer 6/2/2014
Deciphera Pharmaceuticals Announces Initiation Of Phase 1 Cancer Trial For Altiratinib (DCC-2701) MET/TIE2/VEGFR/TRK Kinase Inhibitor For Solid Tumors 5/30/2014
Threshold Pharmaceuticals, Inc. (THLD) Announces Data From Ongoing Phase 1/2 Trial Of TH-302 Plus Dexamethasone In Patients With Relapsed/Refractory Multiple Myeloma 5/30/2014
Threshold Pharmaceuticals, Inc. (THLD) Announces Data From Ongoing Phase 1/2 Trial Of TH-302 Plus Bevacizumab (Avastin®) In Patients With Recurrent Glioblastoma 5/30/2014
Heat Biologics Receives Green Light To Expand Enrollment Of Its Phase 1/2 Study Of HS-410 In Bladder Cancer Based On Encouraging Preliminary Safety Results 5/30/2014
Dilaforette Presents Results From Exploratory Phase 1/2 Clinical Trial In Uncomplicated Malaria 5/30/2014
Benitec Limited (BLT.AX) Commences Patient Dosing With TT-034 In Patients With Hepatitis C 5/29/2014
Symphogen A/S To Report Preliminary Safety And Exploratory Efficacy Data From A Phase 1 Study Of Sym004, Anti-EGFR Monoclonal Antibody Mixture At American Society of Clinical Oncology 5/29/2014
Dyax Corp. (DYAX) Announces Dosing Of First Subject In Phase 1b Trial Of DX-2930 In Patients With Hereditary Angioedema 5/28/2014
Xencor Initiates Phase 1 Study Of XmAb7195 For Asthma 5/28/2014
AtheroNova Inc. (AHRO.OB) Announces Russian Ministry Of Healthcare Approval For Initiation Of Phase 1b Trial Investigating AHRO-001 5/28/2014
Biocryst Pharmaceuticals (BCRX) To Announce Results From The BCX4161 Opus-1 Phase 2 Trial For Hereditary Angioedema May 27 5/27/2014
Tekmira Pharmaceuticals Corporation Initiating Phase1/2 Clinical Trial In Patients With Hepatocellular Carcinoma 5/27/2014
uniQure Announces Successful Transfection Of Liver Cells With AAV5 And Strong Safety Data From Acute Intermittent Porphyria Clinical Trial 5/27/2014
Immune Design Corporation's GLAAS™ Discovery Platform Used In MEDI7510 Phase 1 Trial For Respiratory Syncytial Virus 5/27/2014
Northwest Biotherapeutics (NWBO) Release: Early Positive Responses Seen In Over 50% Of Dcvax®-Direct Patients To Date 5/27/2014
Depymed Announces Validation Of Trodusquemine As A Therapeutic Candidate For HER2-Positive Breast Cancer 5/27/2014
Tekmira Pharmaceuticals Corporation Presents Positive Interim Results on Phase 1/2 Clinical Programs 5/22/2014
Anavex Life Sciences Corp. (AVXL.OB) Reports That New Data Confirms Calcium Target Over-Expression May Be Involved In Causing Alzheimer's Disease 5/22/2014
StemCells Inc. (STEM) Advances Clinical Trial In Age-Related Macular Degeneration To Final Cohort 5/22/2014
Zalicus Inc. (ZLCS) Updates Progress On Z944 Clinical Development 5/22/2014
Amgen (AMGN) Release: The New England Journal of Medicine Publishes Positive Proof-Of-Concept Data For New Asthma Treatment 5/21/2014
Immunomedics, Inc. (IMMU) Reports Results With IMMU-132 In Patients With Pancreatic Cancer 5/21/2014
aTyr Pharma Inc. Completes First Phase 1 Study For Rare Disease Program 5/21/2014
Galena Biopharma  (GALE) To Present GALE-301 Phase 1 Data At The American Society of Clinical Oncology 50th Annual Meeting 5/21/2014
Clovis Oncology (CLVS) Wins Breakthrough Status For Lung Cancer Candidate CO-1686 5/21/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1 Study Of ISIS-PKK Rx 5/20/2014
Immunomedics, Inc. (IMMU) Reports Results With IMMU-132 In Patients With Pancreatic Cancer 5/20/2014
Karyopharm Therapeutics (KPTI) Announces Second Orphan Drug Designation For Selinexor In Diffuse Large B-Cell Lymphoma (DLBCL) 5/19/2014